|
| Sofosbuvir metabolites GS566500 Basic information |
Product Name: | Sofosbuvir metabolites GS566500 | Synonyms: | Sofosbuvir metabolites GS566500;GS-566500;N-[(2'R)-2'-Deoxy-2'-fluoro-2'-methyl-5'-uridylyl]-L-alanine;(2S)-2-(((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoic acid;PSI 352707;Sofosbuvir Impurity 49 (GS-566500);(2S)-2-(((((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)amino)propanoic Acid Ammonium Salt;O-Desisopropyl O-Desphenyl Sofosbuvir Ammonium Salt | CAS: | 1233335-78-8 | MF: | C13H19FN3O9P | MW: | 411.28 | EINECS: | | Product Categories: | | Mol File: | 1233335-78-8.mol | |
| Sofosbuvir metabolites GS566500 Chemical Properties |
density | 1?+-.0.1 g/cm3(Predicted) | solubility | DMSO (Slightly), Methanol (Very Slightly, Heated) | form | Solid | pka | 2.66±0.50(Predicted) | color | Off-White to Pale Beige |
| Sofosbuvir metabolites GS566500 Usage And Synthesis |
Uses | PSI 352707 Ammonium Salt is a metabolite of PSI-7977 (P839640), a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-a-fluoro-b-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. |
| Sofosbuvir metabolites GS566500 Preparation Products And Raw materials |
|